Model Number 106524US |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Hemorrhage/Bleeding (1888); Respiratory Failure (2484); Thrombosis/Thrombus (4440)
|
Event Date 06/30/2022 |
Event Type
Death
|
Manufacturer Narrative
|
No further information was provided.A supplemental report will be submitted once the manufacturer¿s investigation is completed.
|
|
Event Description
|
It was reported that on (b)(6) 2022 the patient's intra operative course was complicated by bleeding (coagulopathy) and vasoplegia which was treated with blood products and factor viii and it resolved without sequelae on (b)(6) 2022.On (b)(6) 2022, the patient was reintubated due to worsening status, labored breathing, tachypnea, and difficulty clearing secretions.On (b)(6) 2022, the patient also had upper extremity swelling and ultrasound revealed an occlusive deep vein thrombosis throughout the left internal jugular vein and the more inferior subclavian vein.In addition, there was an occlusive superficial thrombus throughout the basilic and cephalic veins.On (b)(6) 2022, the patient had a supratheraputic international normalized ratio of 8.5 and 5.2 which stopped the same day.On (b)(6) 2022, it was reported that the patient passed away.
|
|
Manufacturer Narrative
|
Manufacturer's investigation conclusion: a specific cause for the patient outcome could not be conclusively determined through this evaluation.A direct correlation between heartmate 3 left ventricular assist system (lvas), serial number (b)(6), and the reported events and patient outcome could not be conclusively established through this evaluation.Multiple requests for additional information regarding this event were submitted to the account; no response has been received at this time.(b)(6) was not returned for evaluation.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The heartmate 3 left ventricular assist system (lvas) instructions for use (ifu) is currently available.Section 1 ¿introduction¿ of this document lists bleeding, respiratory failure, venous thromboembolism, and death as adverse events that may be associated with the use of the heartmate 3 lvas.Additionally, section 6 ¿patient care and management¿ provides information regarding the recommended anticoagulation therapy and inr (international normalized ratio) range, as well as considerations for when there is a risk of bleeding.Section 6 also outlines indications of thrombus as well as how to respond to such events.No further information was provided.The manufacturer is closing the file on this event.
|
|
Search Alerts/Recalls
|
|